Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PY314 |
Synonyms | |
Therapy Description |
PY314 is a monoclonal antibody that targets TREM2 expressed on tumor-associated macrophages (TAMs), potentially resulting in depletion of M2-like TAMs, activation of the immune response, and anti-tumor activity (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C104). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PY314 | PY-314|PY 314 | PY314 is a monoclonal antibody that targets TREM2 expressed on tumor-associated macrophages (TAMs), potentially resulting in depletion of M2-like TAMs, activation of the immune response, and anti-tumor activity (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C104). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |